Biogen Stock News

Related Stocks: HES , BG , BAH , NEM , GOLD , IP , WLTW , ALIT , TTWO , PSQ , UBER , RDS.A , MA , WPF , WY , TBT , MIME , BIIB ,

Biogen Inc said on Monday its research chief Alfred Sandrock, who led development of its Alzheimer's disease drug Aduhelm, is leaving the company after a 23-year run.

Related Stocks: BIIB , RCI , VICI , CVS , WLTW , ODP , ACT , ACT , XEC , GE , HPLTU , ALX , ALXN , WORK , BABA , MXIM , HIG , CNC ,

The global TNF inhibitors market was valued around US$ 40,369.8 Mn in 2017. It is anticipated to expand at a stable CAGR of 2.54% during the forecast period of 2018 to 2026, according to a new report published by Transparency

Monthly premiums for Medicare Part B beneficiaries are rising significantly in 2022, and the high cost of Biogen''s Alzheimer''s drug is partly to blame.

Biogen earns top ESG leadership scores on areas including Innovation Management and Climate Strategy, highlighting efforts to address urgent and long-term challenges facing humanityIn 2021, Biogen

Biogen earns top ESG leadership scores on areas including Innovation Management and Climate Strategy, highlighting efforts to address urgent and long-term challenges facing humanity In 2021, Biogen notably bolstered its longstanding corporate responsibility

Medicare Premiums Set To Soar; Biden Admin Blames Drug Costs & COVID By Zachary Stieber of the Epoch Times , President Joe Bidens administration on Friday announced it is raising Medicare premiums, a move it blamed in part on the cost of drugs. The Medicare Part B standard monthly premium will rise by nearly $22 to $170.10 next year, the Centers for Medicare & Medicaid Services said. The increase in the Part B premium for 2022 is continued evidence that rising drug costs threaten the affordability and sustainability of the Medicare program, Chiquita Brooks-LaSure, administrator of the agency, said in a statement. The Biden-Harris Administration is working to make drug prices more affordable and equitable for all Americans, and to advance drug pricing reform through competition, innovation, and transparency, she added. The move also stemmed from the limiting of the monthly premium increase this year in the Continuing Appropriations Act and from spending trends driven by COVID-19, the agency said. It also reflects the need to maintain a contingency reserve for unanticipated increases in health care spending, particularly certain drug costs. One drug in particular was a major factor.